Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Importance of Kidney Health in Spina Bifida-Separating Wheat From Chaff.

JAMA network open·2026
Same author

Establishing a clinician-prioritized pediatric urology clinical research agenda in the United States.

Journal of pediatric urology·2026
Same author

Intracranial hypocapnia is associated with parenchymal ischemia and worsened outcomes following stroke.

Journal of neurointerventional surgery·2026
Same author

Survivorship After Testicular Cancer in Adolescents and Young Adults: What is Causing Death and When?

The Journal of urology·2026
Same author

Sex differences in proteomic response to ischemic stroke.

Biology of sex differences·2026
Same author

Sexual Function in Women with Müllerian Anatomic Differences of the Genitourinary Tract-A Qualitative Evaluation.

Journal of pediatric and adolescent gynecology·2026

Related Experiment Video

Updated: Jun 7, 2025

Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
06:09

Quantification of Tumor Cell Adhesion in Lymph Node Cryosections

Published on: February 9, 2020

11.9K

How Many Lymph Nodes are Enough in Paratesticular Rhabdomyosarcoma?

Katelyn A Spencer1, Brittany Levy2, Will Cranford3

  • 1Department of Urology, Division of Pediatric Urology, University of Kentucky, Lexington, KY, USA.

Journal of Pediatric Surgery
|November 11, 2024
PubMed
Summary
This summary is machine-generated.

Accurate staging of paratesticular rhabdomyosarcoma (PT RMS) requires sufficient lymph node evaluation. This study suggests sampling at least 26 lymph nodes (LNs) to minimize the risk of missing occult metastatic disease in PT RMS patients.

Keywords:
Lymph node yieldPara-testicular rhabdomyosarcomaRetroperitoneal lymph node samplingRisk assessmentStaging

More Related Videos

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

1.8K
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.6K

Related Experiment Videos

Last Updated: Jun 7, 2025

Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
06:09

Quantification of Tumor Cell Adhesion in Lymph Node Cryosections

Published on: February 9, 2020

11.9K
Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

1.8K
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.6K

Area of Science:

  • Pediatric Oncology
  • Surgical Oncology
  • Cancer Staging

Background:

  • Accurate lymph node (LN) evaluation is critical for staging paratesticular rhabdomyosarcoma (PT RMS) and guiding treatment.
  • Current methods for determining adequate LN yield (LNY) are based on positivity rates and do not fully account for patient-level variability.
  • There is a need for a refined methodology to quantify the risk of missing involved LNs based on LNY.

Purpose of the Study:

  • To quantify the probability of missing involved lymph nodes in PT RMS based on LN yield (LNY).
  • To compare a novel methodology using a beta-binomial model against current recommendations for LN sampling.
  • To establish an optimal LNY threshold to minimize the risk of false-negative staging in PT RMS.

Main Methods:

  • Utilized the National Cancer Database (NCDB) to identify patients diagnosed with PT RMS between 2004 and 2018.
  • Included patients >10 years and those ≤10 years with clinical N1 (cN1) disease, aligning with Children's Oncology Group (COG) guidelines for retroperitoneal LN sampling (RPLNS).
  • Applied a beta-binomial model to calculate the false-negative rate of RPLNS and determine the LNY threshold for <10% risk of missing occult disease.

Main Results:

  • The study analyzed 62 patients with PT RMS.
  • Median LNY was 17 (IQR 9-28.75), with a median of 2.5 involved LNs (IQR 2-5).
  • The beta-binomial model indicated that a LNY of 26 LNs reduces the chance of missing occult metastatic disease to less than 10%.

Conclusions:

  • Traditional models suggest 7-12 LNs are adequate for staging, but this study provides a more precise quantification.
  • Sampling at least 26 LNs is recommended to achieve a <10% risk of missing occult metastatic disease in most PT RMS patients.
  • Surgeons should consider this evidence-based LNY threshold to improve staging accuracy during RPLNS for PT RMS.